High rates of progressive hepatic functional deterioration whether lamivudine therapy is continued or discontinued after emergence of a lamivudine-resistant mutant: A prospective randomized controlled study

Journal of Gastroenterology

Volumn 41, Issue 3, 2006, Pages 240-249

  Kim, Yoon Jun ^a   Kim, Byeong Gwan ^a   Jung, Jun Oh ^a   Yoon, Jung Hwan ^a   Lee, Hyo Suk ^a  

^a Seoul National University   (South Korea)

Author keywords

Chronic hepatitis B; Hepatic decompensation; Hepatitis B virus; Lamivudine; Lamivudine resistant mutant

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SERUM ALBUMIN; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KOREA; LIVER FAILURE; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOCYTE COUNT; VIROLOGY;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; BILIRUBIN; BIOLOGICAL MARKERS; DISEASE PROGRESSION; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; KOREA; LAMIVUDINE; LIVER FAILURE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PLATELET COUNT; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROTHROMBIN TIME; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; SERUM ALBUMIN;

EID: 39049173952     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-005-1750-5     Document Type: Article

References (26)

1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337: 1733-45.
2. Niederau C, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alpha for chronic hepatitis B. N Engl J Med 1996;334:1422-7.
3. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during longterm lamivudine therapy. Gastroenterology 2003;124:105- 17.
4. Consensus statements on the prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. Core Working Party for Asia-Pacific Consensus on Hepatitis B and C. J Gastroenterol Hepatol 2000;15:825-41.
5. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34: 1225-41.
6. Melegari M, Scaglioni PP, Wands Jr. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998;27:628-33.
7. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30: 567-72.
8. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001;12 Suppl 1:67-71.
9. Kim JW, Lee HS, Woo GH, Yoon JH, Jang JJ, Chi JG, et al. Fatal submassive hepatic necrosis associated with tyrosine-methionineaspartate- aspartate-motif mutation of hepatitis B virus after longterm lamivudine therapy. Clin Infect Dis 2001;33:403-5.
10. Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology 2000;32:635- 9.
11. Liaw YF, Chien RN, Yeh CT. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antivir Ther 2004;9:257-62.
12. Wong VW, Chan HL, Wong ML, Tam JS, Leung NW. Clinical course after stopping lamivudine in chronic hepatitis B patients with lamivudine-resistant mutants. Aliment Pharmacol Ther 2004;19:323-9.
13. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
14. Hong SP, Kim NK, Hwang SG, Chung HJ, Kim S, Han JH, et al. Detection of hepatitis B virus YMDD variants using mass spectrometric analysis of oligonucleotide fragments. J Hepatol 2004; 40:837-44.
15. Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003;36:687-96.
16. Lau DT, Khokhar MF, Doo E, Ghany MG, Herion D, Park Y, et al. Long-term therapy of chronic hepatitis B with lamivudine. Hepatology 2000;32:828-34.
17. Nafa S, Ahmed S, Tavan D, Pichoud C, Berby F, Stuyver L, et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32:1078-88.
18. Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A, Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000;32:847-51.
19. Papatheodoridis GV, Dimou E, Laras A, Papadimitropoulos V, Hadziyannis SJ. Course of virologic breakthroughs under longterm lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002;36:219-26.
20. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001;33:1527-32.
21. Yuen MF, Kato T, Mizokami M, Chan AO, Yuen JC, Yuan HJ, et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003;39:850- 5.
22. de Man RA, Bartholomeusz AI, Niesters HG, Zondervan PE, Locarnini SA. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. J Hepatol 1998;29: 669-75.
23. Malik AH, Lee WM. Hepatitis B therapy: the plot thickens. Hepatology 1999;30:579-81.
24. Shimada N, Yamamoto K, Kuroda MJ, Terada R, Hakoda T, Shimomura H, et al. HBcAg-specific CD8 T cells play an important role in virus suppression, and acute flare-up is associated with the expansion of activated memory T cells. J Clin Immunol 2003;23:223-32.
25. Perrillo R, Hann HW, Mutimer D, Willems B, Leung N, Lee WM, et al. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004;126:81-90.
26. Peters MG, Hann Hw H, Martin P, Heathcote EJ, Buggisch P, Rubin R, et al. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004;126:91-101.